CAV-1, StatSa Signaling, and Estrogen-Dependent Breast Cancer The human Caveolin-1 (Cav-1) gene acts as a mammary gland tumor suppressor. We have previously identified Cav-1 inactivating (dominant-negative (DN)) mutations in up to 35 % of estrogen receptor (ER) positive breast cancer patients. Our hypothesis is that up-regulation of ER levels and activity are caused by Cav-1 inactivating mutations. As Cav-1 functions as an inhibitor of the Jak-2 kinase, we propose that StatSa activation is the mechanism by which loss of Cav-1 function results in increased ER-alpha levels. In support of this hypothesis, we present novel evidence that StatSa activation is sufficient to upregulate ER-alpha levels in ER-negative human breast cancer cells. As such, our preliminary studies have now defined a novel signaling pathway leading to breast cancer: Cav-1 gene inactivation (DN-mutations) -->StatSa activation --> ER-alpha upreoulation ->Cvclin D1 over-expression. The three Specific Aims of the project are: 1) Determine the role of StatSa activation and ER-alpha in Cav-1-related mammary hyperplasia. proliferation, and 3D lumen formation. We will analyze the mammary glands of Cav-1/StatSa double- knockout mice and study the ex vivo behavior of primary cultures of mammary epithelia from these mice. 2) Determine the role of StatSa activation and ER-alpha in Cav-1-related mammary tumorigenesis and metastasis. For this purpose, we will perform orthotopic transplantation of Met-1 cells expressing Cav-1 dominant-negative (DN) mutants (such as P132L) that are found in human breast cancer. The role of StatSa signaling will be assessed using DN mutants of StatSa and Jak-2. The role of estrogen will be assessed by ovariectomy and supplementation with estrogen pellets. Tamoxifen-resistance will also be investigated. 3) Determine if Cav-1 mutations co-segregate with StatSa activation in ER(+) human breast cancer samples. Here, we propose to examine the relevance of this newly defined signaling pathway in human breast cancer pathogenesis, using Cav-1 mutations, ER-alpha expression levels, and StatSa activation as novel prognostic markers. Since greater than 40% of ER-apha positive patients show tamoxifen-resistance, we will also examine if Cav-1 mutations and StatSa activation are critical predictors of tamoxifen-resistance.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Mohla, Suresh
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Thomas Jefferson University
Schools of Medicine
United States
Zip Code
Danilo, Christiane; Gutierrez-Pajares, Jorge L; Mainieri, Maria Antonietta et al. (2013) Scavenger receptor class B type I regulates cellular cholesterol metabolism and cell signaling associated with breast cancer development. Breast Cancer Res 15:R87
Trimmer, Casey; Bonuccelli, Gloria; Katiyar, Sanjay et al. (2013) Cav1 suppresses tumor growth and metastasis in a murine model of cutaneous SCC through modulation of MAPK/AP-1 activation. Am J Pathol 182:992-1004
Capparelli, Claudia; Chiavarina, Barbara; Whitaker-Menezes, Diana et al. (2012) CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, ""fueling"" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 11:3599-610
Carito, Valentina; Bonuccelli, Gloria; Martinez-Outschoorn, Ubaldo E et al. (2012) Metabolic remodeling of the tumor microenvironment: migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. Cell Cycle 11:3403-14
Guido, Carmela; Whitaker-Menezes, Diana; Lin, Zhao et al. (2012) Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. Oncotarget 3:798-810
Sotgia, Federica; Martinez-Outschoorn, Ubaldo E; Howell, Anthony et al. (2012) Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 7:423-67
Chiavarina, Barbara; Martinez-Outschoorn, Ubaldo E; Whitaker-Menezes, Diana et al. (2012) Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1? and HIF2? in tumor-associated fibroblasts and human breast cancer cells. Cell Cycle 11:3280-9
Capparelli, Claudia; Guido, Carmela; Whitaker-Menezes, Diana et al. (2012) Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle 11:2285-302
Capparelli, Claudia; Whitaker-Menezes, Diana; Guido, Carmela et al. (2012) CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 11:2272-84
Mercier, Isabelle; Camacho, Jeanette; Titchen, Kanani et al. (2012) Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol 181:278-93

Showing the most recent 10 out of 80 publications